16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
Epistemonikos ID: 3bac439b0d33a6e6b40b0bd5b6d39e3927aa8123
First added on: May 11, 2024